Jon Kuwahara files SEC Form 4 disclosures for Novus Therapeutics, Inc.. They have made 1 open-market trade across 1 company since 2019, most recently 2019-05-21.
CIK 0001664784
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVUS | 7,032 | $103K |
Shares reported on the most recent Form 4, priced at the 2019-05-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVUS | SELL | 2019-05-20 | 2019-05-22 | $1.95 | $10K | -9.9% | -42.7% | -57.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.